Clinical Trial Update: VTX958 Versus Placebo for the Treatment of Moderate to Severe Psoriasis [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating VTX958 vs placebo for moderate to severe psoriasis was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• VTX958

Snippet

Sponsor: Ventyx Biosciences, Inc | Conditions: Psoriasis | Phase 2 | Status: TERMINATED